Vascular basement membrane-derived multifunctional peptide (VBMDMP) gene (fusion gene of the human immunoglobulin G3 upper hinge region and two tumstatin-derived fragments) obtained by chemical synthesis was cloned into vector pUC19, and introduced into the expression vector pGEX-4T-1 to construct a prokaryotic expression vector pGEX-4T-1-VBMDMP. Recombinant VBMDMP produced in Escherichia coli has been shown to have significant activity of antitumor growth and antimetastasis in Lewis lung carcinoma transplanted into mouse C57Bl/6. In the present study, we have studied the ability of rVBMDMP to inhibit endothelial cell tube formation and proliferation, to induce apoptosis in vitro, and to suppress tumor growth in vivo. The experimental results showed that rVBMDMP potently inhibited proliferation of human endothelial (HUVEC-12) cells and human colon cancer (SW480) cells in vitro, with no inhibition of proliferation in Chinese hamster ovary (CHO-K1) cells. rVBMDMP also significantly inhibited human endothelial cell tube formation and suppressed tumor growth of SW480 cells in a mouse xenograft model. These results suggest that rVBMDMP is a powerful therapeutic agent for suppressing angiogenesis and tumor growth.
The development of new blood vessels from pre-existing ones is generally referred to as angiogenesis [1] . In adults, angiogenesis is critical for normal physiological events, such as wound repair, the ovarian cycle, and endometrium remodeling [2] . However, uncontrolled neovascularization is associated with a number of pathological disorders including diabetic retinopathy and rheumatoid arthritis, as well as tumor growth and metastasis [3, 4] . Tumor growth and metastasis require angiogenesis, and this process is pivotal to the survival and subsequent growth of solid tumors larger than a few cubic millimeters in size [3] . Expansion of tumor mass occurs not only by perfusion of blood through the tumor but also by paracrine stimulation of tumor cells, several growth factors and matrix proteins produced by the new capillary endothelium [3] . A number of angiogenesis inhibitors have been identified, namely angiostatin, endostatin, restin, pigment epithelium-derived factor, canstatin and tumstatin [4−7] .
Vascular basement membrane is composed of macromolecules such as type IV collagen, laminin, heparan sulfate proteoglycans, fibronectin, and entactin [8] . Type IV collagen is one of the major macromolecule constituents of basement membrane, which promotes adhesion, migration, differentiation and growth of cells. Type IV collagen is expressed as six distinct α chains, namely α1− α6, assembles into triple helices and further forms a network to provide a scaffold for other macromolecules in basement membranes [9, 10] . These α chains are composed of three domains, the N-terminal 7s domain, the middle triple helical domain, and the C-terminal globular noncollagenous domain [11] . Tumstatin consists of 244 a.a., including 12 a.a. from the triple helical domain located http://www.abbs.info; www.blackwellpublishing.com/abbs in the C-terminal region, and 232 a.a. derived from the Cterminal noncollagenous domain [7] . Recombinant tumstatin exhibits anti-angiogenic and antitumoral properties through two distinct peptide sequences [7] . A specific sequence from tumstatin, comprising residues 197−215, inhibited melanoma cell proliferation as well as melanoma cell invasive properties [12, 13] . Maeshima et al. [7] demonstrated that the anti-angiogenic activity of tumstatin is localized to a.a. 54−132 using deletion mutagenesis. Subsequently, the anti-angiogenic activity was localized to a 25 a.a. region encompassing a.a. 74−98, which contains the entire anti-angiogenic activity associated with tumstatin [14] . However, the antitumor cell activity is not realized until the peptide region is exposed by trunction of tumstatin, a requirement not essential for the anti-angiogenic activity of this domain [7] . Some scientists speculate that some part of tumstatin comformation impedes the binding of the functional domain of tumstatin with its receptor, which affects the activity [7] .
In previous studies, we constructed a fusion gene of the human immunoglobulin (Ig) G3 upper hinge region and two tumstatin-derived specific sequences, and expected to realize the antitumor cell proliferation and antiangiogenic activities. The fusion sequence encodes the vascular basement membrane-derived multifunctional peptide (VBMDMP) [15] . The activity of VBMDMP in vivo was evaluated using recombinant fusion protein of glutathione-VBMDMP produced in Escherichia coli. The recombinant VBMDMP significantly inhibited tumor growth and metastasis in a mouse lung carcinoma model [16] .
In the present report, we demonstrated that rVBMDMP selectively inhibits endothelial cell and human colon cancer cell proliferation and induces apoptosis of endothelial cells in vitro. It also suppresses human colon cancer xenograft growth in BALB/c-nu mouse.
Materials and Methods
Production of recombinant VBMDMP and synthetic peptides rVBMDMP was produced in E. coli using pGEX-4T-1-VBMDMP and purified as described previously [16] . Synthetic peptide TMPFLFCNVNDVCNFASRNDYSYWL (tumstatin-derived a.a. 74−98) and peptide CNYYSN-SYSFWLASLNPER (tumstatin-derived a.a. 197−215) were provided by Xi'an Huacheng Biotechnology (Xi'an, China). The tumstatin-derived a.a. 74−98 peptide was supplied as a white freeze-dried powder, with a molecular weight of 3.218 kDa, at a purity of more than 95%. The tumstatin derived a.a. 197−215 peptide was also supplied as a white freeze-dried powder. Its molecular weight is 2.315 kDa, and its purity is of more than 95%.
Cell lines and cell culture
Human umbilical vein endothelial HUVEC-12 cell line, human colon cancer SW480 cell line and Chinese -ovary CHO-K1 cell line were all obtained from the China Center for Type Culture Collection (Wuhan, China). HUVEC-12 cells were maintained in Dulbecco's minimum essential medium (Clonetics, Walkersville, USA) supplemented with 15% fetal calf serum, 100 U/ml penicillin, and 100 μg/ml streptomycin. SW480 and CHO-K1 cell lines were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum, 100 U/ml penicillin, and 100 μg/ml streptomycin (Life Technology, New York, USA) at 37 ºC in a 5% CO 2 incubator. where T is absorbance in treated group; U is that in untreated group; and B is that in the vehicle control group [17] .
Apoptosis assay by flow cytometer using propidium iodide (PI) staining
Cells were treated with various concentrations of rVBMDMP, synthetic peptide, TNP-470 (o-chloracetylcarbamoyl-fumagillol) and 5-FU for 48 h, then harvested with 0.25% trypsin and washed with PBS. Cells at a density of 1×10 6 were fixed in 70% ice-cold EtOH/PBS for 20 min on ice, then washed with PBS and incubated in PI solution (69 mM PI, 388 mM sodium citrate, 100 μg/ml RNase A) for 15 min at 37 ºC. Cells were immediately analyzed with FAC Scan flow cytometry (Becton Dickinson, San Jose, USA) [18] .
Apoptosis detection by morphological observation after acridine orange (AO) staining
Cells were treated with various concentrations of rVBMDMP for 48 h, then harvested with 0.25% trypsin and resuspended in RPMI 1640 medium. After staining for 10 min with 4 ml of 100 mg/ml AO, cells were visualized immediately under a fluorescence microscope (TE2000-S; Nikon, USA) [19] .
Endothelial tube assay
Matrigel (Collaborative Biomolecules, Bedford, USA) was added (320 μl) to each well of a 24-well plate and allowed to polymerize [20] . A suspension of 2.5×10 4 HUVEC-12 cells in Dulbecco's minimum essential medium without antibiotics was passed into each well coated with Matrigel. The cells were treated with either rVBMDMP or bovine serum albumin (BSA). In control group, cells were incubated with sterile PBS. All assays were carried out in triplicate. Cells were incubated for 24 h at 37 ºC and viewed using a CK 2 Olympus microscope (magnification, 4× ocular, 10× objective; Olympus, CX41-12000, Japan). The cells were then photographed using a digital photocamera. Ten fields were viewed, and tubes were counted and averaged [21] .
In vivo tumor studies
Female BALB/c-nu mice, 4 weeks old and each weighing approximately 16 g, were implanted with 2×10 6 SW480 cells into the subcutis of the back. Tumor length and width were measured using a vernier caliper, and tumor volume was calculated using the standard formula [5] :
Tumor volume=length×width 2 ×0.52
When the tumors were approximately 100 mm 3 , the animals were divided into groups, four in each group. Initial doses of rVBMDMP or positive and vehicle controls were given on day 1, then injected intraperitoneally every 2 d at the doses indicated. Mice were weighed twice each week. Tumor volume was calculated every 4 d. Volume was plotted over the treatment period. The mice were weighed, killed, and their tumors were excised.
Tumor inhibition=Volume(treated)/Volume(control)×100%
where, Volume(treated) is the volume of the tumor of treated group; and Volume(control) is the volume of the tumor of the vehicle control group.
Statistical analysis
All data were presented as mean±SD. ANOVA with a one-tailed Student's t-test was used to identify significant differences in multiple comparisons. A level of P<0.05 was considered statistically significant. Fig. 2(B) ].
Results

Effects
Effect of rVBMDMP on endothelial cell tube formation
When HUVEC-12 cells are cultured on Matrigel, they rapidly align and form hollow tube-like structures. rVBMDMP significantly inhibited the ability of endothelial cell tube formation in a concentration-dependent manner compared with the BSA control (Fig. 3) .
Effect of rVBMDMP on endothelial cell apoptosis
Apoptotic cells were detected by morphological observation after AO staining and quantified as the proportion of cells that had a DNA content of less than 2 N (sub-G1 DNA content) [22] . As shown in Fig. 4 , AO staining revealed that rVBMDMP (1.0 μM) promoted apoptosis in HUVEC-12 cells [ Fig. 4(B) ], whereas PBS did not induce the apoptosis of HUVEC-12 cells [Fig. 4(A) We examined the effect of rVBMDMP on an established primary human tumor model in nude mice. rVBMDMP significantly inhibited the growth of human colon cancer xenografts in a dose-dependent manner (Fig. 5) .
rVBMDMP at 10 mg/kg inhibited tumor growth similar to cyclophosphamide (100 mg/kg) and TNP-470 (20 mg/ kg) (Fig. 5) . A significant inhibitory effect on human colon cancer was observed on day 20 (control, 1184±125.0 mm 
Fig. 4 Effect of recombinant vascular basement membranederived multifunctional peptide (rVBMDMP) on the apoptosis of human umbilical vein endothelial cells (HUVEC-12)
HUVEC-12 cells were treated by rVBMDMP for 48 h, and apoptosis cells were detected by morphological observation after acridine orange staining (A and B) and assayed by flow cytometer using propidium iodide staining (C). Each point represents the mean±SD of triplicate wells. This experiment was repeated three times. *P<0.05 vs. phosphate-buffered saline (PBS) group; **P<0.01 vs. PBS group by one-tailed Student's t-test. TNP-470, o-chloracetylcarbamoylfumagillol. day 20 was also observed, and we found that the inhibitory rate in tumors treated with rVBMDMP at dosages of 1 mg/kg, 5 mg/kg and 10 mg/kg was 62%, 66% and 75%, respectively.
Discussion
The formation of new capillaries from pre-existing vessels, angiogenesis, is essential for the process of tumor growth and metastasis [23] . The switch to an angiogenic phenotype requires both the upregulation of angiogenic stimulators and the downregulation of angiogenesis inhibitors. Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor are angiogenic factors abundantly expressed in tumors. Vascularized tumors might http://www.abbs.info; www.blackwellpublishing.com/abbs overexpress one or more of these angiogenic factors, which can synergistically promote tumor growth. Inhibition of a single angiogenic factor, such as VEGF, with a receptor antagonist might not be enough to arrest tumor growth, because tumor subpopulations that produce angiogenic factors other than VEGF can still influence tumor growth [24] . A number of angiogenesis inhibitors have been identified and certain factors such as platelet factor-4 [25] , and PEX (a fragment of MMP-2, which comprises the Cterminal hemopexin-like domain) [26] are not endogenously associated with tumor cells. In contrast, angiostatin [4] and endostatin [5] are tumor-associated angiogenesis inhibitors generated by the tumor tissue itself. Recently, Maeshima et al. reported the capacity of tumstatin [7, 14] to inhibit the proliferation of vascular endothelial cells and the formation of new blood vessels using in vitro and in vivo models of angiogenesis and tumor growth [7] . A synthetic peptide (a.a. 197−215) corresponding to the C-terminal portion of tumstatin was reported to bind to αvβ3 integrin [29] . Tumstatin (a.a. 197−215) synthetic peptide inhibits melanoma cell proliferation and binds the αvβ3 receptor, but it is not responsible for the anti-angiogenic activity of tumstatin [7] . In contrast, tumstatin (a.a. 74− 98) synthetic peptide, but not the peptide sequence 197− 215, had anti-angiogenic properties without any antitumor cell activity. Experiment indicated the anti-angiogenic activity residing within these amino acid residues is effective even when it is part of a full-length folded tumstatin. Interestingly, the antitumor cell activity residing within the peptide sequence 197−215 is not available when present as part of the full-length tumstatin. The activity imparted on the melanoma cells by the amino acid sequence 197− 215 is only realized when this peptide is exposed either by truncation of the molecule [7] or by synthesis of a representative peptide [12] .
Recently, we designed and synthesized a fusion peptide combination of tumstatin-derived peptides a.a. 74−98 and a.a. 197−215 by the human IgG3 upper hinge region which possesses anti-angiogenic and antitumor cell proliferation properties, named VBMDMP [15] . VBMDMP was produced in E. coli. rVBMDMP has been demonstrated to possess significant biological activities of antitumor growth and antimetastasis in Lewis lung carcinoma transplanted into C57Bl/6 mice [16] . Whether rVBMDMP functions by selectively suppressing the proliferation of vascular endothelial cells and tumor cells remains to be elucidated.
In the present paper, we showed that rVBMDMP and tumstatin (a.a. 197−215) synthetic peptide potently inhibited the proliferation of SW480 cells, but had no effect on the proliferation of CHO-K1 cells, indicating rVBMDMP possesses activity of tumstatin (a.a. 197−215) peptide and is selective for tumor cells. Maeshima et al. reported tumstatin (a.a. 74−98) synthetic peptide effectively inhibited vascular endothelial cell proliferation, but did not suppress melanoma cells [7] . Our results also confirmed tumstatin (a.a. 74−98) synthetic peptide did not influence the growth and proliferation of SW480.
Recent studies demonstrated that tumstatin (a.a. 197− 215) synthetic peptide could inhibit the proliferation of various tumor cells [14, 30] , however, the antitumor cell activity residing within the peptide sequence 197−215 is not available when present as part of the full-length of tumstatin [7] . A shorter peptide comprising the seven Nterminal residues 197−203 (CNYYSNS) shares the same inhibitory profile. The 3-D structures of the CNYYSNS and tumstatin (a.a. 197−215) peptide show a β-turn at the YSNS (200−203) sequence level, which is crucial for biological activity [31] . Our structural studies using Antheprot software (Version 4.3c) wave analysis indicated that, as both ends of the IgG3 upper hinge region sequence were rarefaction structures, these peptides could act as potent and specific antitumor inhibitors in tumor progression [15] . So, rVBMDMP could show the antitumor cell activity of tumstatin (a.a. 197−215) synthetic peptide.
Anchorage of tumor cells to basement membrane proteins is mediated in part by integrins, a large family of heterodimeric cell surface receptors, that function not only as cell adhesion receptors but also as signaling receptors regulating cell growth, cell death, migration, and tissue remodeling [32, 33] . Maeshima et al. [34] characterized in detail the tumstatin (a.a. 197−215) synthetic peptide binding site on αvβ3 integrin and provided evidence that the peptide specifically interacts with the β subunit of αvβ3 integrin. Expression of αvβ3 integrin is highly distinct, with lower expression in endothelial cells in resting state and Chinese hamster ovary cells, and high expression in activated vascular cells, smooth muscle cells, osteoclast and various tumor cells such as melanoma, human lung cancer and human prostate adenocarcinoma cells [34−37] . A peptide sequence corresponding to residues 197−215 in tumstatin was able to inhibit in vitro tumor cell proliferation and migration through reconstituted basement membranes. The peptide sequence contains an SNS triplet in position 201−203 that is unique to the α3(IV) collagen chain and replacement of each of the two serine residues by an alanine abolished its biological activity [12, 13] . Tentative affinity chromatography of melanoma cell extract on a tumstatin 197−215 peptide column identified αv3 integrin as the tumor cell receptor [27] . Floquet et al. demonstrated that a specific sequence from tumstatin, comprising residue 197−215, inhibited melanoma cell proliferation as well as melanoma cell invasive properties [31] . This inhibitory effect was mediated through binding of the tumstatin (a.a. 197−215) synthetic peptide to αvβ3 integrin and affected the binding and the activation of pro-MMP-2 at the plasma membrane by decreasing both MT1-MMP and β3 integrin expression [13, 38] . Indeed, numerous studies have reported that the expression of αvβ3 integrin is correlated to high invasive abilities in tumor cell lines [39] . Our results indicated that although tumstatin (a.a. 197−215) synthetic peptide inhibits human colon cancer cell proliferation, it is not responsible for the anti-angiogenic activity of rVBMDMP.
In this study, the effect of rVBMDMP on the growth and proliferation in HUVEC-12 cells was investigated. We found that rVBMDMP, tumstatin (a.a. 74−98) synthetic peptide, and TNP-470, an analog of fumagillin, significantly reduced the growth and proliferation of HUVEC-12 cells, whereas tumstatin (a.a. 197−215) synthetic peptide did not. These results indicated that rVBMDMP retains anti-angiogenic activity of tumstatin (a.a. 74−98) synthetic peptide. It was reported that tumstatin (a.a. 74−98) peptide inhibits proliferation and induces apoptosis specifically in endothelial cells [14] . The peptides, similar to tumstatin, bind and function through αvβ3 integrin in an RGD (arginine-glycine-asparagine)-independent manner. Maeshima et al. reported that tumstatin and tumstatin (a. a. 74−98) synthetic peptide function as endothelial cellspecific inhibitors of protein synthesis. Through a requisite interaction with αvβ3 integrin, tumstatin and tumstatin (a.a. 74−98) synthetic peptide inhibit activity of focal adhesion kinase, phosphatidylinositol 3-kinase, protein kinase B and mammalian target of rapamycin. They also prevent the dissociation of eukaryotic initiation factor 4E protein from 4E-binding protein 1, indicating a role for integrins in mediating cell-specific inhibition of Cap-dependent protein synthesis and suggesting a potential mechanism for tumstatin's selective effects on endothelial cells [40] . Whether rVBMDMP inhibits the proliferation of HUVEC-12 cells by binding with αvβ3 integrin in mediating endothelial cell-specific inhibition of Cap-dependent protein synthesis, inducing endothelial cell apoptosis, remains to be investigated using the proteome technique.
This research also investigated the effect of rVBMDMP on tumor growth of human colon cancer xenograft in a mouse model. Experimental results showed that rVBMDMP suppressed the growth of tumor xenografts in a dosedependent manner. The potency of rVBMDMP on the inhibitory effect of tumor growth of human cancer xenografts in the mouse model was as much as 20 times that of cyclophosphamide or TNP-470. In addition, rVBMDMP had no effect on the weight of experimental animals, indicating rVBMDMP was not toxic (data not shown). The data reported here suggest that rVBMDMP facilitates two unique antitumor activities, and this will make it a valuable therapeutic agent for inhibition of tumor growth.
